NYSE:PTHS | Free Cash Flow | Pelthos Therapeutics Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2022-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$13.13M$194,000.00-$13.32M
2025-12-31-$6.25M
2025-03-31-$632,000.00$0.00-$632,000.00
2024-12-31-$670,000.00
2024-03-31-$1.99M
2023-12-31-$356,807.00
2023-03-31-$173,369.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$22.59M$99,000.00-$22.69M
2024-12-31-$5.79M$0.00-$5.79M
2023-12-31-$981,031.00
2022-12-31-$1.57M